Maze Therapeutics jumps on early data for kidney disease drug

Shares of drug developer Maze Therapeutics MAZE.O rise 35% to $21.77 premarket

Company says its experimental oral drug, MZE782, showed strong results in an early-stage trial

The drug, which blocks a protein called SLC6A19, led to a sharp increase in the amounts of phenylalanine and glutamine excreted in urine

Company says it plans to begin mid-stage studies in 2026 for phenylketonuria, a rare genetic disorder, and chronic kidney disease, a long-term condition affecting kidney function

No serious side-effects were reported in the study, which tested the drug in 112 healthy adults, company says

As of last close, stock up 0.4% YTD